Do you want to read an article? Please log in or register.
Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes
Type 2 Diabetes
COMMENTED
Related content
Diabetes - GeneralType 2 DiabetesGlycemic Control
Faster Aspart Versus Insulin Aspart As Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
Diabetes Care.
Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW
doi: 10.2337/dc16-1770.
Diabetes - GeneralType 1 Diabetes
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1)
Diabetes Care.
Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM
doi: 10.2337/dc16-1771.
COMMENTED
Type 1 DiabetesPediatric Diabetes
Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
Diabetes Care.
Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, Ekelund M, Larsen SF, Danne T
doi: 10.2337/dc19-0009.
COMMENTED
Type 2 DiabetesGlycemic Control
A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-2232.
Type 2 Diabetes
Contribution of basal and postprandial hyperglycaemia in type 2 diabetes patients treated by an intensified insulin regimen: Impact of pump therapy in the OPT2mise trial
Diabetes Obes Metab.
Reznik Y, Habteab A, Castaneda J, Shin J, Joubert M
doi: 10.1111/dom.13398.
COMMENTED
Diabetes - General
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus
Ann Intern Med.
Roglic G, Norris SL
doi: 10.7326/M18-1149.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
Diabetes Care.
Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frias J, Roussel R, Bolli GB
doi: 10.2337/dc18-0559.
COMMENTED
Type 2 Diabetes
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab.
Landgraf W, Owens DR, Frier BM, Zhang M, Bolli GB
doi: 10.1111/dom.13897.
Type 2 Diabetes
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
Diabet Med.
Meneghini L, Doshi A, Gouet D, Vilsbøll T, Begtrup K, Őrsy P, Ranthe MF, Lingvay I
doi: 10.1111/dme.14178.